HER-2 overexpression is a negative predictive factor for recurrence in patients with non-muscle-invasive bladder cancer on intravesical therapy
G Moustakas, S Kampantais…�- Journal of�…, 2020 - journals.sagepub.com
Journal of International Medical Research, 2020•journals.sagepub.com
Objective HER-2 is overexpressed in a variety of human malignant tumors and has been
widely used in the prognosis and treatment of breast cancer. In urothelial cell carcinoma of
the bladder, some reports have shown an association between HER-2 overexpression and
worse outcomes. The aim of this study was to examine the association between HER-2
expression and other clinicopathologic parameters in 48 patients treated for primary non-
muscle-invasive transitional cell carcinoma of the bladder. Methods The initial expression of�…
widely used in the prognosis and treatment of breast cancer. In urothelial cell carcinoma of
the bladder, some reports have shown an association between HER-2 overexpression and
worse outcomes. The aim of this study was to examine the association between HER-2
expression and other clinicopathologic parameters in 48 patients treated for primary non-
muscle-invasive transitional cell carcinoma of the bladder. Methods The initial expression of�…
Objective
HER-2 is overexpressed in a variety of human malignant tumors and has been widely used in the prognosis and treatment of breast cancer. In urothelial cell carcinoma of the bladder, some reports have shown an association between HER-2 overexpression and worse outcomes. The aim of this study was to examine the association between HER-2 expression and other clinicopathologic parameters in 48 patients treated for primary non-muscle-invasive transitional cell carcinoma of the bladder.
Methods
The initial expression of HER-2 in tumor specimens and its expression upon disease recurrence following instillation therapy (BCG, Mitomycin, or Epirubicin) were studied.
Results
HER-2 expression was significantly increased between these two timepoints. In multivariate analysis, HER-2 expression at the time of diagnosis was found to be the only independent factor and was associated with reduced recurrence free survival.
Conclusions
HER-2 status could be an additional biomarker for predicting the outcome of non-muscle-invasive bladder cancer, which could help identify high-risk patients for recurrence and possible progression who require close observation and perhaps radical treatment, such as early cystectomy.
Sage Journals